ILMN logo
ILMN
Illumina

Rising Regulations And Fierce Competition Will Impede Clinical Sequencing

Published
16 Apr 25
Updated
09 Aug 25
AnalystLowTarget's Fair Value
US$75.00
26.1% overvalued intrinsic discount
09 Aug
US$94.56
Loading
1Y
-24.1%
7D
-3.9%

Author's Valuation

US$75.0

26.1% overvalued intrinsic discount

AnalystLowTarget Fair Value

Narrative
Updates3

Shared on07 May 25
Fair value Decreased 14%

Read more

Shared on30 Apr 25
Fair value Decreased 2.86%

AnalystLowTarget made no meaningful changes to valuation assumptions.

Read more

Shared on23 Apr 25
Fair value Increased 28%

AnalystLowTarget made no meaningful changes to valuation assumptions.

Read more